Hypotension with dobutamine: β-Adrenergic antagonist selectivity at low doses of carvedilol

Jo Ann Lindenfeld, Brian D. Lowes, Michael R. Bristow

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

OBJECTIVE: To report a case of marked hypotension resulting from the concomitant use of low-dose carvedilol and intravenous dobutamine. CASE SUMMARY: A 54-year-old white man with severe heart failure was placed on carvedilol 3.125 mg orally twice a day; three days later the dosage was increased to 6.25 mg orally twice a day. His symptoms of heart failure worsened with increasing fluid retention, orthopnea, paroxysmal nocturnal dyspnea, and elevated blood urea nitrogen and creatinine. He was admitted for treatment of decompensated heart failure with intravenous dobutamine. With each increase in intravenous dobutamine, systolic blood pressure fell. Dobutamine was discontinued when systolic blood pressure reached 56 mm Hg. In a subsequent admission for decompensated heart failure, when the patient was not taking carvedilol, he was treated with intravenous dobutamine and systolic blood pressure increased. DISCUSSION: Although carvedilol is a nonselective β-adrenergic antagonist, at low doses it is a selective β1- adrenergic antagonist. Dobutamine is a β1-, β2-, and α1-adrenergic agonist. Typically, patients with heart failure treated with intravenous dobutamine have a small increase in systolic blood pressure. We propose that the drop in blood pressure with dobutamine in this patient was caused by a fall in systemic vascular resistance due to vascular β2-adrenergic receptor activation. The normal increase in cardiac output was partially blocked by selective β1-adrenergic blockade at low doses of carvedilol. CONCLUSIONS: β-adrenergic blockade with carvedilol is now common therapy for patients with congestive heart failure. Intravenous dobutamine is often used when these patients have worsening heart failure. Recognition that treatment with dobutamine in patients taking low doses of carvedilol may result in hypotension is important for appropriate monitoring and therapy.

Original languageEnglish (US)
Pages (from-to)1266-1269
Number of pages4
JournalAnnals of Pharmacotherapy
Volume33
Issue number12
DOIs
StatePublished - Dec 1999

Fingerprint

Adrenergic Antagonists
Dobutamine
Hypotension
Blood Pressure
Heart Failure
Adrenergic Agents
Paroxysmal Dyspnea
carvedilol
Adrenergic Agonists
Blood Urea Nitrogen
Therapeutics
Cardiac Output
Vascular Resistance
Adrenergic Receptors
Blood Vessels
Creatinine

Keywords

  • Carvedilol
  • Dobutamine
  • Heart failure

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Hypotension with dobutamine : β-Adrenergic antagonist selectivity at low doses of carvedilol. / Lindenfeld, Jo Ann; Lowes, Brian D.; Bristow, Michael R.

In: Annals of Pharmacotherapy, Vol. 33, No. 12, 12.1999, p. 1266-1269.

Research output: Contribution to journalArticle

@article{296e63935d6e4a13b3a1b991e71c9d38,
title = "Hypotension with dobutamine: β-Adrenergic antagonist selectivity at low doses of carvedilol",
abstract = "OBJECTIVE: To report a case of marked hypotension resulting from the concomitant use of low-dose carvedilol and intravenous dobutamine. CASE SUMMARY: A 54-year-old white man with severe heart failure was placed on carvedilol 3.125 mg orally twice a day; three days later the dosage was increased to 6.25 mg orally twice a day. His symptoms of heart failure worsened with increasing fluid retention, orthopnea, paroxysmal nocturnal dyspnea, and elevated blood urea nitrogen and creatinine. He was admitted for treatment of decompensated heart failure with intravenous dobutamine. With each increase in intravenous dobutamine, systolic blood pressure fell. Dobutamine was discontinued when systolic blood pressure reached 56 mm Hg. In a subsequent admission for decompensated heart failure, when the patient was not taking carvedilol, he was treated with intravenous dobutamine and systolic blood pressure increased. DISCUSSION: Although carvedilol is a nonselective β-adrenergic antagonist, at low doses it is a selective β1- adrenergic antagonist. Dobutamine is a β1-, β2-, and α1-adrenergic agonist. Typically, patients with heart failure treated with intravenous dobutamine have a small increase in systolic blood pressure. We propose that the drop in blood pressure with dobutamine in this patient was caused by a fall in systemic vascular resistance due to vascular β2-adrenergic receptor activation. The normal increase in cardiac output was partially blocked by selective β1-adrenergic blockade at low doses of carvedilol. CONCLUSIONS: β-adrenergic blockade with carvedilol is now common therapy for patients with congestive heart failure. Intravenous dobutamine is often used when these patients have worsening heart failure. Recognition that treatment with dobutamine in patients taking low doses of carvedilol may result in hypotension is important for appropriate monitoring and therapy.",
keywords = "Carvedilol, Dobutamine, Heart failure",
author = "Lindenfeld, {Jo Ann} and Lowes, {Brian D.} and Bristow, {Michael R.}",
year = "1999",
month = "12",
doi = "10.1345/aph.19111",
language = "English (US)",
volume = "33",
pages = "1266--1269",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "12",

}

TY - JOUR

T1 - Hypotension with dobutamine

T2 - β-Adrenergic antagonist selectivity at low doses of carvedilol

AU - Lindenfeld, Jo Ann

AU - Lowes, Brian D.

AU - Bristow, Michael R.

PY - 1999/12

Y1 - 1999/12

N2 - OBJECTIVE: To report a case of marked hypotension resulting from the concomitant use of low-dose carvedilol and intravenous dobutamine. CASE SUMMARY: A 54-year-old white man with severe heart failure was placed on carvedilol 3.125 mg orally twice a day; three days later the dosage was increased to 6.25 mg orally twice a day. His symptoms of heart failure worsened with increasing fluid retention, orthopnea, paroxysmal nocturnal dyspnea, and elevated blood urea nitrogen and creatinine. He was admitted for treatment of decompensated heart failure with intravenous dobutamine. With each increase in intravenous dobutamine, systolic blood pressure fell. Dobutamine was discontinued when systolic blood pressure reached 56 mm Hg. In a subsequent admission for decompensated heart failure, when the patient was not taking carvedilol, he was treated with intravenous dobutamine and systolic blood pressure increased. DISCUSSION: Although carvedilol is a nonselective β-adrenergic antagonist, at low doses it is a selective β1- adrenergic antagonist. Dobutamine is a β1-, β2-, and α1-adrenergic agonist. Typically, patients with heart failure treated with intravenous dobutamine have a small increase in systolic blood pressure. We propose that the drop in blood pressure with dobutamine in this patient was caused by a fall in systemic vascular resistance due to vascular β2-adrenergic receptor activation. The normal increase in cardiac output was partially blocked by selective β1-adrenergic blockade at low doses of carvedilol. CONCLUSIONS: β-adrenergic blockade with carvedilol is now common therapy for patients with congestive heart failure. Intravenous dobutamine is often used when these patients have worsening heart failure. Recognition that treatment with dobutamine in patients taking low doses of carvedilol may result in hypotension is important for appropriate monitoring and therapy.

AB - OBJECTIVE: To report a case of marked hypotension resulting from the concomitant use of low-dose carvedilol and intravenous dobutamine. CASE SUMMARY: A 54-year-old white man with severe heart failure was placed on carvedilol 3.125 mg orally twice a day; three days later the dosage was increased to 6.25 mg orally twice a day. His symptoms of heart failure worsened with increasing fluid retention, orthopnea, paroxysmal nocturnal dyspnea, and elevated blood urea nitrogen and creatinine. He was admitted for treatment of decompensated heart failure with intravenous dobutamine. With each increase in intravenous dobutamine, systolic blood pressure fell. Dobutamine was discontinued when systolic blood pressure reached 56 mm Hg. In a subsequent admission for decompensated heart failure, when the patient was not taking carvedilol, he was treated with intravenous dobutamine and systolic blood pressure increased. DISCUSSION: Although carvedilol is a nonselective β-adrenergic antagonist, at low doses it is a selective β1- adrenergic antagonist. Dobutamine is a β1-, β2-, and α1-adrenergic agonist. Typically, patients with heart failure treated with intravenous dobutamine have a small increase in systolic blood pressure. We propose that the drop in blood pressure with dobutamine in this patient was caused by a fall in systemic vascular resistance due to vascular β2-adrenergic receptor activation. The normal increase in cardiac output was partially blocked by selective β1-adrenergic blockade at low doses of carvedilol. CONCLUSIONS: β-adrenergic blockade with carvedilol is now common therapy for patients with congestive heart failure. Intravenous dobutamine is often used when these patients have worsening heart failure. Recognition that treatment with dobutamine in patients taking low doses of carvedilol may result in hypotension is important for appropriate monitoring and therapy.

KW - Carvedilol

KW - Dobutamine

KW - Heart failure

UR - http://www.scopus.com/inward/record.url?scp=0033384584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033384584&partnerID=8YFLogxK

U2 - 10.1345/aph.19111

DO - 10.1345/aph.19111

M3 - Article

C2 - 10630826

AN - SCOPUS:0033384584

VL - 33

SP - 1266

EP - 1269

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 12

ER -